Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-304-2499
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings DateN/A
OptionableNot Optionable
Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions
What is Trevi Therapeutics' stock symbol?
Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."
What price target have analysts set for TRVI?
5 brokerages have issued 1-year price targets for Trevi Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Trevi Therapeutics' share price to reach $16.75 in the next year. This suggests a possible upside of 111.2% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.
What is the consensus analysts' recommendation for Trevi Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.
Has Trevi Therapeutics been receiving favorable news coverage?
Media coverage about TRVI stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trevi Therapeutics earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Trevi Therapeutics.
Who are some of Trevi Therapeutics' key competitors?
Some companies that are related to Trevi Therapeutics include Milestone Pharmaceuticals (MIST), Revance Therapeutics (RVNC), Obseva (OBSV), Dermira (DERM), Magenta Therapeutics (MGTA), Akebia Therapeutics (AKBA), Puma Biotechnology (PBYI), ChemoCentryx (CCXI), GlycoMimetics (GLYC), CytomX Therapeutics (CTMX), Basilea Pharmaceutica (BPMUF), Beyondspring (BYSI), Provention Bio (PRVB), Progenics Pharmaceuticals (PGNX) and Corbus Pharmaceuticals (CRBP).
What other stocks do shareholders of Trevi Therapeutics own?
Who are Trevi Therapeutics' key executives?
Trevi Therapeutics' management team includes the folowing people:
- Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
- Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
- Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
- Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
- Dr. Amale Hawi, Sr. VP of CMC (Age 65)
When did Trevi Therapeutics IPO?
(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.
When did the company's quiet period expire?
Trevi Therapeutics' quiet period expired on Monday, June 17th. Trevi Therapeutics had issued 5,500,000 shares in its initial public offering on May 7th. The total size of the offering was $55,000,000 based on an initial share price of $10.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Trevi Therapeutics?
Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevi Therapeutics' stock price today?
One share of TRVI stock can currently be purchased for approximately $7.93.
How big of a company is Trevi Therapeutics?
What is Trevi Therapeutics' official website?
How can I contact Trevi Therapeutics?
Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]
MarketBeat Community Rating for Trevi Therapeutics (NASDAQ TRVI)
MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote "Outperform" if you believe TRVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days.
